Abstract 18721: Results of a Patient Survey Assessing Knowledge of Anticoagulation Control and Therapy - A Report from the Michigan Anticoagulation Quality Improvement Initiative
Background: Previous studies have found that a lack in a patient’s knowledge of warfarin therapy directly correlates to poor adherence, which may in turn lead to poor anticoagulation management. It is essential that patients receive proper educational support concerning anticoagulation. This is essential in regard to the identification of potential adverse events. In our study, we sought to identify potential knowledge gaps in patients enrolled in the Michigan Anticoagulation Quality Improvement Initiative (MAQI2).
Methods: MAQI2 is a Blue Cross Blue Shield of Michigan sponsored consortium of anticoagulation management services seeking to improve the safety and quality of care provided to patients taking warfarin. To examine the efficacy of patient education, patients were asked to complete a survey including questions from the validated Oral Anticoagulation Knowledge (OAK) Test. Two MAQI2 consortium sites participated in the survey. The survey was provided within two weeks of the educational session. The survey was voluntary and completed by patients with no monetary benefit.
Results: Between October 2012 and July 2013, 405 surveys were provided to patients. 146 patients completed the survey, an overall response rate of 36%. Surveys with missing answers were not included in the analysis. Four questions were identified as “key questions” based on clinical relevance and are listed in Table 1. Only 25% of patients answered all key questions correctly. The most commonly missed questions concerned indications to seek medical attention, identification of interacting medications, and the importance of a consistent diet.
Discussion: Despite education efforts provided by anticoagulation services within the MAQI2 consortium, there were significant knowledge gaps in clinically relevant topics. Efforts to improve patient education should be ongoing. The goal of these efforts should be to improve understanding and promote retention of these important lessons.
- Patient education/teaching psychosocial aspects
- Patient safety
- Quality improvement
Author Disclosures: S.T. Heidt: None. C. Alexandris-Souphis: None. X. Gu: None. E. Kline-Rogers: None. G.D. Barnes: None. B. Haymart: None. E. Puroll: None. S. Watts: None. R. Kozlowski: None. G.D. Krol: None. S. Kaatz: Research Grant; Modest; Boehringer-Ingelheim, Bristol Myers Squibb, Bayer/Jansen/Johnson and Johnson, Eisai, Iverson Genetics/Diagnostics/Medicare, National Institute of Health, Canadian Institute of Health Research, Blue Cross/Blue Shield of Michigan. Honoraria; Modest; Jansen/Johnson and Johnson, Boehringer-Ingelheim, GlaxoSmithKline. Consultant/Advisory Board; Modest; Boehringer-Ingelheim, Bristol Myers Squibb/Pfizer, Jansen/Johnson and Johnson, Daiichi Sankyo, AC Forum, National Certification Board of Anticoagulation Providers, National Blood Clot Alliance Medical and Scientific Advisory Board. J.B. Froehlich: Research Grant; Modest; Sanofi-Aventis, Blue Cross/Blue Shield of Michigan, Mardigian Foundation, Fibromuscular Dysplasia Society of America. Consultant/Advisory Board; Modest; Sanofi-Aventis, Ortho-McNeil, Merck. J.H. Kozlowski: None.
- © 2014 by American Heart Association, Inc.